Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAP3K5 antisense RNA 1 (MAP3K5-AS1) is a long noncoding RNA transcribed from the MAP3K5 locus in the antisense direction. It can regulate the expression of the MAP3K5 gene via transcriptional interference, chromatin modification, or influencing alternative splicing. Since MAP3K5 (apoptosis signal-regulating kinase 1) is implicated in apoptosis, oxidative stress, inflammation, and multiple diseases, the regulatory function of MAP3K5-AS1 may affect these biological processes and associated disease risk indirectly. There is no evidence that MAP3K5-AS1 itself is a classical therapeutic target, but its modulation of MAP3K5 expression suggests possible roles in health and disease, which are under ongoing research. MAP3K5-AS1 is not a protein, receptor, ion channel, or enzyme but rather a regulatory RNA, categorized as a long noncoding antisense RNA. Its primary biological role is to modulate expression of the sense gene (MAP3K5) by either interfering with transcription, changing epigenetic marks, or affecting mRNA processing. While MAP3K5 (the protein-coding gene) is a well-known therapeutic target, MAP3K5-AS1 is not directly targeted by drugs or clinical interventions. Antisense RNAs like MAP3K5-AS1 can regulate their sense partners in either cis (locally at the locus) or trans (at other chromosomal locations, somewhat more rarely), often by interfering with transcription, promoting mRNA degradation, or modifying splicing. MAP3K5-AS1 is a long noncoding RNA associated with regulation of MAP3K5 expression, with its disease associations and clinical relevance still being investigated. It is not itself a therapeutic target, but its activity may influence the function of MAP3K5, which is a target in diseases such as cardiovascular conditions, diabetes, and cancer.
Not applicable directly; antisense RNA mechanisms may include transcriptional interference, altering mRNA splicing, stability, or translation of MAP3K5.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MAP3K5 antisense RNA 1 (MAP3K5-AS1).